Stocksigma LogoStocksigma Logo

Lupin Launches Raltegravir Tablets in US with 180-Day Generic Exclusivity

Lupin Limited has launched Raltegravir Tablets USP, 600 mg in the US following US FDA approval for its ANDA

Lupin Launches Raltegravir Tablets in US with 180-Day Generic Exclusivity

Lupin Ltd 路 Press Release 路 04 Nov 2026, 1:08 am

Lupin Launches Raltegravir Tablets in US with 180-Day Generic Exclusivity Lupin Limited has launched Raltegravir Tablets USP, 600 mg in the US following US FDA approval for its ANDA. The product is bioequivalent to Merck Sharp & Dohme's reference listed drug Isentress HD Tablets, 600 mg, indicated for HIV-1 treatment. As the exclusive first-to-file applicant, Lupin is eligible for 180-day generic drug exclusivity. According to IQVIA MAT Sep'26 data, Raltegravir Tablets USP, 600 mg recorded estimated annual US sales of USD 26 million.

Original exchange filing (PDF)

More announcements from Lupin Ltd

All Lupin Ltd announcements